23-Sep-2016
Few data are available on the potential benefits that achieving different HbA1c targets might deliver. Dr Samiul Mostafa, a Diabetes Trials Unit academic clinical lecturer, used the UKPDS Outcomes Model to estimate 10-year risks for micro- and macrovascular type 2 diabetes complications when targeting HbA1c levels between 10% and 6%, to quantify the likely incremental benefits. These simulated outcomes could provide patients and clinicians a guide to the potential glucose-lowering benefits possible when targeting progressively lower HbA1c values from a baseline of 10%.